Blood Coagulation Disorders
Conditions
Brief summary
ROTEM® sigma is a new thromboelastometric coagulation analysis system. The new system is fully automated allowing for a simple and safe operation compared to its predecessor model ROTEM® delta. Method comparison of ROTEM® sigma with predecessor model ROTEM® delta) - confirmation of equality. Confirmation of reference intervals of the ROTEM® systems.
Detailed description
The main innovation of ROTEM® sigma is the development of a sample handler and a cartridge allowing for a of full automated test operation. As in ROTEM® delta four different tests can be run simultaneously on the four channels of the analyser. Whereas the tests in ROTEM® delta are performed manually by pipetting a blood sample and liquid system reagents, in ROTEM® sigma the reagents are contained in freeze dried pellet form in a cartridge. Test operation is performed by inserting a cartridge and attaching a blood sample to the analyser. The five available ROTEM® tests INTEM, EXTEM, FIBTEM, APTEM, and HEPTEM are contained in different combinations in two cartridge configurations: * Cartridge type 1 including INTEM, EXTEM, FIBTEM, APTEM * Cartridge type 2 including INTEM, EXTEM, FIBTEM, HEPTEM Aim of the study is the performance evaluation of the new ROTEM® sigma coagulation analyzer in comparison to the current ROTEM® delta thromboelastometry system. As a valid method comparison requires test results that cover the whole measurement range of the test system it is also necessary to include acute bleeding and emergency patients in the study. Only the inclusion of acute bleeding and emergency patients will produce strong pathologic test results allowing for a valid evaluation of the test system.
Interventions
DEVICEROTEM sigma
Group Healthy Volunteers: a blood sample is tested with ROTEM sigma Group Patients with expected coagulopathy: a blood sample is tested with ROTEM sigma and ROTEM delta in parallel
Sponsors
Tem Innovations GmbH
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Patients: * Age ≥ 18 years * Informed written consent * Patients with an acute bleeding during surgery * Or: trauma patients with acute bleeding * Or: hypercoagulable (above normal fibrinogen) patients at the ICU Healthy Volunteers: * Adult healthy individuals (≥ 18 years) * Written informed consent
Exclusion criteria
Patients: • none Healthy Volunteers: * Any indications of alcohol or illegal drug abuse * Any chronic disease with possible effect on the coagulation (liver disease, coronary heart disease) * Any acute illness within the last 14 days * Any hemostasis associated disease (myocardial infarction, thrombosis , stroke etc.) within the last year * Intake of any coagulation affecting medication (aspirin, pain-killers, anti-rheumatic drugs, marcumar, platelet inhibitors) within the last 14 days * Females only: known pregnancy * Females only: breast feeding * Any indication for any hemostasis disorder as interrogated by a specific history of bleeding tendencies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Method comparison: linear regression analysis and bias estimation at medical decision limits | Parameter differences assessed at time of blood sampling |
Countries
Austria, Switzerland, United States
Contacts
Primary ContactVolker Friemert, Dr.
Backup ContactKlaus Görlinger, Dr.
Outcome results
None listed